Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Liabilities and Shareholders Equity (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $56.1 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 44.64% to $56.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $298.8 million through Dec 2025, up 195.06% year-over-year, with the annual reading at $56.1 million for FY2025, 44.64% down from the prior year.
  • Liabilities and Shareholders Equity hit $56.1 million in Q4 2025 for Connect Biopharma Holdings, down from $67.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $127.4 million in Q4 2023 to a low of $56.1 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $87.9 million across 3 years, with a median of $87.7 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 20.48% in 2024 and later plummeted 44.64% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $127.4 million in 2023, then dropped by 20.48% to $101.3 million in 2024, then tumbled by 44.64% to $56.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CNTB at $56.1 million in Q4 2025, $67.4 million in Q3 2025, and $82.7 million in Q2 2025.